Welcome to our dedicated page for Prime Medicine SEC filings (Ticker: PRME), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Reading Prime Medicine’s latest 10-K can feel like decoding advanced genetics—hundreds of pages on Prime Editing science, clinical-trial risk, and cash runway. If you’ve ever searched for “Prime Medicine SEC filings explained simply” or wondered how to spot pivotal 8-K trial disclosures before the market reacts, this page solves that problem. Stock Titan’s AI scans each document the moment it hits EDGAR, flagging what matters to biotech investors—pipeline milestones, collaboration revenue, and dilution warnings.
Use our platform to jump directly to the numbers and narratives that drive valuation. Need the “Prime Medicine quarterly earnings report 10-Q filing” to track R&D spend? Curious about “Prime Medicine insider trading Form 4 transactions” after fresh data releases? Our real-time engine delivers plain-language synopses, side-by-side charts, and instant alerts. We also translate dense proxy language—think “Prime Medicine proxy statement executive compensation”—into clear tables and context.
- “Prime Medicine annual report 10-K simplified” with AI-generated section summaries
- “Prime Medicine earnings report filing analysis” highlighting cash burn and runway
- “Prime Medicine Form 4 insider transactions real-time” for scientist and CEO trades
- “Prime Medicine 8-K material events explained” within minutes of publication
- “Understanding Prime Medicine SEC documents with AI” through interactive cues
- “Prime Medicine executive stock transactions Form 4” for pattern spotting
Whether you follow gene-editing breakthroughs or monitor dilution risk, our comprehensive coverage and AI-powered summaries turn complex filings into actionable insight—saving hours and improving decision quality.
Prime Medicine, Inc. (PRME) – Form 4 insider transaction
Director and 10% owner David R. Liu disclosed the purchase of 21,000 shares of Prime Medicine common stock on 23-Jun-2025. The trade was executed under a previously adopted Rule 10b5-1 plan dated 3-Mar-2025, indicating it was pre-scheduled rather than opportunistic.
The weighted-average purchase price was $2.162 per share, with individual trades occurring between $2.06 – $2.25. Following the transaction, Liu’s direct ownership increased to 20,219,945 shares, an incremental addition of roughly 0.10 % to his existing stake.
No derivative securities were reported, and no sales occurred. While the absolute dollar value of the purchase (~$45,400) is modest relative to Liu’s overall holding, insider buying—especially by a high-ownership director—can be interpreted as a vote of confidence in the company’s prospects at current price levels.
FAQ
What is the current stock price of Prime Medicine (PRME)?
What is the market cap of Prime Medicine (PRME)?
What is the core technology behind Prime Medicine?
Which therapeutic areas does Prime Medicine focus on?
How does Prime Medicine generate revenue?
What differentiates Prime Medicine from other gene editing companies?
How does Prime Medicine ensure the safety and efficacy of its treatments?
What role do strategic partnerships play in Prime Medicine's business model?
How does Prime Medicine address challenges in genetic therapies?
What are the key clinical milestones for Prime Medicine?
